BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29685422)

  • 1. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
    Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of high serum CXCL13 level in Waldenström macroglobulinemia.
    Wu YY; Cai H; Zhao AL; Zhang L; Zhou DB; Cao XX; Li J
    Leuk Res; 2019 Jun; 81():50-55. PubMed ID: 31015152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients.
    Terpos E; Tasidou A; Eleftherakis-Papaiakovou E; Christoulas D; Gavriatopoulou M; Gkotzamanidou M; Roussou M; Kastritis E; Papadaki T; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):115-7. PubMed ID: 21454208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
    García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
    Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
    Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
    Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.
    Kristinsson SY; Björkholm M; Landgren O
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):187-90. PubMed ID: 23490991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
    Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
    Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
    Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
    Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
    Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and Prognosis of Patients with Immunoglobulin M Monoclonal Gammopathy.
    Tanaka H; Sakuma Y; Ikeda H; Shimizu R; Sugita Y; Iwai R
    J Clin Exp Hematop; 2017; 57(2):47-53. PubMed ID: 29021514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
    Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
    Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis in Waldenström's macroglobulinemia.
    Terpos E; Tasidou A; Kastritis E; Eleftherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Dimopoulos MA
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):46-9. PubMed ID: 19362971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cellular origin and malignant transformation of Waldenström macroglobulinemia.
    Paiva B; Corchete LA; Vidriales MB; García-Sanz R; Perez JJ; Aires-Mejia I; Sanchez ML; Barcena P; Alignani D; Jimenez C; Sarasquete ME; Mateos MV; Ocio EM; Puig N; Escalante F; Hernández J; Cuello R; García de Coca A; Sierra M; Montes MC; González-López TJ; Galende J; Bárez A; Alonso J; Pardal E; Orfao A; Gutierrez NC; San Miguel JF
    Blood; 2015 Apr; 125(15):2370-80. PubMed ID: 25655603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
    J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
    Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
    Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
    Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
    Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
    Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
    Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
    Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
    Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.